Historically, considering these beneficial effects of acute β-AR signaling, the use of β-adrenergic agonists or PDE inhibitors has been speculated to be beneficial for patients with MI and heart failure [231,250]. This evidence concerns the gene ADRB2 and myocardial infarction.